Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BTXA-51 by Edgewood Oncology for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
BTXA-51 is under clinical development by Edgewood Oncology and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...
BTXA-51 by Edgewood Oncology for Refractory Acute Myeloid Leukemia: Likelihood of Approval
BTXA-51 is under clinical development by Edgewood Oncology and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
BTXA-51 by Edgewood Oncology for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
BTXA-51 is under clinical development by Edgewood Oncology and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
BTXA-51 by Edgewood Oncology for Solid Tumor: Likelihood of Approval
BTXA-51 is under clinical development by Edgewood Oncology and currently in Phase II for Solid Tumor. According to GlobalData, Phase...